The Latest Breaking News from AMGN

Drug manufacturing giant Amgen is expected to announce its fourth-quarter results in the upcoming month and analysts expect single-digit growth in earnings.

Learn how diversification, careful screening, and key metrics like payout ratios and yields can help build a strong, income-generating portfolio for the long term.

The Dogs of the Dow is a long standing wall street strategy for investing in the stock market that involves purchasing the 10 highest yielding Dow Jones stocks.

The biotech sector’s AI-driven advancements, personalized medicine demand, and streamlined regulations fuel significant market growth. Hence, investors should consider robust biotech stocks such as Vertex Pharmaceuticals (VRTX), Amgen (AMGN), and Gilead Sciences (GILD). Read on.

Biotech companies are making monumental strides in cancer treatment, leveraging cutting-edge technologies to redefine the field. Given the robust prospect, investors looking for fundamentally sound biotech stocks might consider adding Regeneron Pharmaceuticals (REGN), Amgen (AMGN), and Gilead Sciences (GILD) to their portfolio. Read on….

Despite pharma giant Amgen trailing behind the Dow index over the past three months, analysts remain cautiously bullish about the stock's growth potential.

As breakthroughs in biotechnology accelerate, the sector is primed for significant expansion. With emerging trends like gene editing and precision medicine transforming healthcare, fundamentally solid biotech stocks such as Amgen (AMGN), Gilead Sciences (GILD), and Biogen (BIIB) are gaining traction. With promising innovations, these stocks could be prime investment opportunities.…

Amgen has underperformed the broader market over the past year, but analysts are moderately optimistic about the stock’s prospects.

With increasing chronic diseases, demand for personalized medicines, and adoption of AI, the biotech market is booming. Therefore, it could be wise to invest in solid biotech stocks Amgen (AMGN), Regeneron Pharmaceuticals (REGN), and Gilead Sciences (GILD) for substantial returns. Read more.

Investors seeking growth and dividend income in the healthcare sector may want to consider Eli Lilly, Gilead Sciences, and Amgen, which have delivered impressive returns and boast strong pipelines and strategic moves.

Amgen will release its third-quarter earnings this month, and analysts anticipate a single-digit bottom-line growth.